



US008697109B2

(12) **United States Patent**
Garner et al.

(10) **Patent No.:** **US 8,697,109 B2**
(45) **Date of Patent:** ***Apr. 15, 2014**

(54) **CAGED MERCAPTAN AND SELENO-MERCAPTAN COMPOUNDS AND METHODS OF USING THEM**

(75) Inventors: **William Garner**, Eastport, ME (US);
Margaret Garner, Eastport, ME (US);
Ronald D. Blum, Roanoke, VA (US)

(73) Assignee: **Encore Health, LLC**, Roanoke, VA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 710 days.

This patent is subject to a terminal disclaimer.

4,210,667 A	7/1980	Sarges et al.
4,755,528 A	7/1988	DuPriest et al.
5,395,356 A	3/1995	King et al.
5,459,133 A	10/1995	Neufeld
5,465,737 A	11/1995	Schachar
5,466,680 A	11/1995	Rudy
5,476,515 A	12/1995	Kelman et al.
5,488,050 A	1/1996	Neufeld
5,503,165 A	4/1996	Schachar
5,527,774 A	6/1996	Girard
5,529,076 A	6/1996	Schachar
5,624,955 A	4/1997	Nagasawa et al.
5,665,770 A	9/1997	Terao et al.
5,686,450 A	11/1997	Hellberg et al.
5,688,828 A	11/1997	Hellberg et al.
5,691,379 A	11/1997	Ulrich et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0 369 880	5/1990
WO	WO 93/25166	12/1993

(Continued)

(21) Appl. No.: **12/267,260**

(22) Filed: **Nov. 7, 2008**

(65) **Prior Publication Data**

US 2009/0124683 A1 May 14, 2009

Related U.S. Application Data

(60) Provisional application No. 61/033,870, filed on Mar. 5, 2008, provisional application No. 61/060,487, filed on Jun. 11, 2008, provisional application No. 61/077,186, filed on Jul. 1, 2008.

(51) **Int. Cl.**
A61F 2/02 (2006.01)

(52) **U.S. Cl.**
USPC **424/423**

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,238,224 A	3/1966	Ohara et al.
3,855,240 A	12/1974	Mueller

Al-Ghoul, K. J., R. K. Nordgren, A. J. Kuszak, C. D. Freel, M. J. Costello, and J. R. Kuszak, 2001. Structural evidence of human nuclear fiber compaction as a function of ageing and cataractogenesis. *Experimental eye research* 72: 199-214.

(Continued)

Primary Examiner — Carlos Azpuru
(74) *Attorney, Agent, or Firm* — Sterne, Kessler, Goldstein & Fox PLLC

(57) **ABSTRACT**

Novel mercaptan compounds, particularly those including a photolabile protecting group, are described as well as methods of using the compounds for the prevention and treatment of ocular damage and disease.

38 Claims, 12 Drawing Sheets

